Supplemental Tables for:
Association between Skin Reaction and Clinical Benefit in Patients Treated with Anti-PD-1 Monotherapy for Advanced Non-Small Cell Lung Cancer
Mari Aso et al.

Table S1. Association between EGFR mutation and best response

Variables	With EGFR mutation[a] (n = 17)	Without EGFR mutation[b] (n = 138)	P
Objective response rate, No. (%)[c]	2(12%)	47(34%)	.095[e]
Disease control rate, No. (%)[d]	8(47%)	97(70%)	.096[e]

[a]Patients with epidermal growth factor receptor mutation.
[b]Patients without epidermal growth factor receptor mutation.
[c]Proportion of patients achieving complete or partial response based on modified Response Evaluation Criteria in Solid Tumors version 1.1.
[d]Proportion of patients achieving complete response, partial response, or stable disease based on modified Response Evaluation Criteria in Solid Tumors version 1.1.
[e]By Fisher's exact test.

TableS2. Association between EGFR mutation and Skin reaction

	With EGFR mutation[a] (n = 17)	Without EGFR mutation[b] (n = 138)	P
With skin reaction	4(24%)	47(34%)	0.55[c]
Without skin reaction	13(76%)	91(66%)	

[a]Patients with epidermal growth factor receptor mutation.
[b]Patients without epidermal growth factor receptor mutation.
[c]By Chi-squared test.

Table S3. Association between Skin reaction and best response in EGFR positive group

Variables	With skin reaction[a] (n = 4)	Without skin reaction[b] (n = 13)	P
Objective response rate, No. (%)[c]	2(50%)	0(0%)	0.04[e]
Disease control rate, No. (%)[d]	4(100%)	4(30%)	0.02[e]

[a]Patients who developed skin reaction during nivolumab or pembrolizumab monotherapy.
[b]Patients who did not develop skin reaction during nivolumab or pembrolizumab monotherapy.
[c]Proportion of patients achieving complete or partial response based on modified Response Evaluation Criteria in Solid Tumors version 1.1.
[d]Proportion of patients achieving complete response, partial response, or stable disease based on modified Response Evaluation Criteria in Solid Tumors version 1.1.
[e]By Fisher's exact test.

Table S4. Association between the Presence of Skin Reactions and Treatment Responses in patients with known TPS

	With Skin reaction[a] (n = 27)	Without Skin reaction[b] (n = 63)	P
Best response, CR/PR/SD/PD	0/14/13/0	0/14/27/22	
Objective response rate, No. (%)[c]	14(50%)	14(22%)	.011[e]
Disease control rate, No. (%)[d]	27(100%)	41(65%)	.001[e]

TPS; Tumor proportion score; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

[a]Patients who developed skin reactions during nivolumab or pembrolizumab monotherapy.

[b]Patients who did not develop skin reactions during nivolumab or pembrolizumab monotherapy.

[c]Proportion of patients achieving complete or partial response based on modified Response Evaluation Criteria in Solid Tumors version 1.1.

[d]Proportion of patients achieving complete response, partial response, or stable disease based on modified Response Evaluation Criteria in Solid Tumors version 1.1.

[e]By Chi-squared test.

Table S5. Association between the Presence of Skin Reactions and

Treatment Responses in patients with TPS ≥50%

	With Skin reaction[a] (n = 15)	Without Skin reaction[b] (n = 18)	P
Best response, CR/PR/SD/PD	0/11/4/0	0/8/7/3	
Objective response rate, No. (%)[c]	11(73%)	8(44%)	.16[c]
Disease control rate, No. (%)[d]	15(100%)	15(83%)	.23[c]

TPS; Tumor proportion score; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
[a]Patients who developed skin reactions during nivolumab or pembrolizumab monotherapy.
[b]Patients who did not develop skin reactions during nivolumab or pembrolizumab monotherapy.
[c]Proportion of patients achieving complete or partial response based on modified Response Evaluation Criteria in Solid Tumors version 1.1.
[d]Proportion of patients achieving complete response, partial response, or stable disease based on modified Response Evaluation Criteria in Solid Tumors version 1.1.
[e]By Fisher's exact test.